Pros and cons of subcutaneous (SC) versus intravenous (IV) administration of immune checkpoint inhibitors in non-small cell lung cancer.
作者信息
Moeller Julie, Green Michael D, Ramnath Nithya
机构信息
Oncology Specialty Pharmacy Services, Charles S. Kettles VA Medical Center, Ann Arbor, MI, USA.
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
出版信息
Transl Lung Cancer Res. 2024 Jun 30;13(6):1444-1449. doi: 10.21037/tlcr-24-111. Epub 2024 Jun 18.
Abstract
摘要
相似文献
1
Pros and cons of subcutaneous (SC) versus intravenous (IV) administration of immune checkpoint inhibitors in non-small cell lung cancer.非小细胞肺癌中皮下注射与静脉注射免疫检查点抑制剂的利弊
Transl Lung Cancer Res. 2024 Jun 30;13(6):1444-1449. doi: 10.21037/tlcr-24-111. Epub 2024 Jun 18.
2
IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.IMscin001 第二部分：一项随机、III 期、开放性、多中心研究，评估阿特珠单抗皮下与静脉给药治疗既往治疗的局部晚期或转移性非小细胞肺癌的药代动力学、疗效、免疫原性和安全性，并与其他已批准适应症进行药代动力学比较。
Ann Oncol. 2023 Aug;34(8):693-702. doi: 10.1016/j.annonc.2023.05.009. Epub 2023 Jun 1.
3
Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.免疫检查点抑制剂联合化疗作为一线治疗非鳞状非小细胞肺癌的疗效和安全性：一项荟萃分析和间接比较。
Ann Palliat Med. 2021 Mar;10(3):2766-2775. doi: 10.21037/apm-20-1498. Epub 2021 Feb 1.
4
Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.一项评估皮下注射阿特珠单抗治疗局部晚期或转移性非小细胞肺癌患者的 1b 期剂量发现研究结果。
Clin Pharmacol Drug Dev. 2021 Oct;10(10):1142-1155. doi: 10.1002/cpdd.936. Epub 2021 Mar 31.
5
Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system.免疫检查点抑制剂在非小细胞肺癌中的不良反应：临床试验和 FDA 药物警戒系统的安全性分析。
Front Immunol. 2024 Apr 30;15:1396752. doi: 10.3389/fimmu.2024.1396752. eCollection 2024.
6
The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.免疫检查点抑制剂治疗非小细胞肺癌和黑色素瘤的安全性和耐受性差异：网状Meta分析和系统评价
Front Pharmacol. 2019 Oct 24;10:1260. doi: 10.3389/fphar.2019.01260. eCollection 2019.
7
Relative Efficacies of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Treatment of Recurrent Non-Small Cell Lung Cancer after Surgery.表皮生长因子受体酪氨酸激酶抑制剂与免疫检查点抑制剂治疗非小细胞肺癌术后复发的相对疗效。
Oncology. 2024;102(6):476-483. doi: 10.1159/000534814. Epub 2023 Nov 20.
8
Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.延长生存：免疫检查点抑制剂在广泛期小细胞肺癌治疗中的作用。
Oncologist. 2020 Nov;25(11):981-992. doi: 10.1634/theoncologist.2020-0193. Epub 2020 Sep 23.
9
Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer.非小细胞肺癌免疫检查点抑制剂的临床试验研究现状与应用
Front Oncol. 2023 Sep 1;13:1213297. doi: 10.3389/fonc.2023.1213297. eCollection 2023.
10
Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials.免疫检查点抑制剂治疗晚期非小细胞肺癌的严重免疫相关不良事件：一项随机临床试验的网络荟萃分析。
Cancer Immunol Immunother. 2022 Sep;71(9):2239-2254. doi: 10.1007/s00262-022-03140-5. Epub 2022 Feb 6.
引用本文的文献
1
Hyaluronidase: structure, mechanism of action, diseases and therapeutic targets.透明质酸酶：结构、作用机制、疾病及治疗靶点
Mol Biomed. 2025 Jul 12;6(1):50. doi: 10.1186/s43556-025-00299-y.
2
Catalase Activity in the Brain Is Associated with Recovery from Brain Injury in a Piglet Model of Traumatic Brain Injury.过氧化氢酶活性与创伤性脑损伤仔猪模型的脑损伤恢复相关。
Brain Sci. 2025 Jun 4;15(6):608. doi: 10.3390/brainsci15060608.
3
On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC.即将到来：为初治卡介苗无反应的高危非肌肉浸润性膀胱癌患者提供新兴疗法的全球多学科视角
Oncol Ther. 2025 Apr 17. doi: 10.1007/s40487-025-00334-6.
本文引用的文献
1
Adopting Weight-Based Dosing With Pharmacy-Level Stewardship Strategies Could Reduce Cancer Drug Spending By Millions.采用基于体重的给药方式，并辅以药剂科层面的管理策略，每年可节省数百万癌症治疗药物的费用。
Health Aff (Millwood). 2023 Jul;42(7):946-955. doi: 10.1377/hlthaff.2023.00102.
2
IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.IMscin001 第二部分：一项随机、III 期、开放性、多中心研究，评估阿特珠单抗皮下与静脉给药治疗既往治疗的局部晚期或转移性非小细胞肺癌的药代动力学、疗效、免疫原性和安全性，并与其他已批准适应症进行药代动力学比较。
Ann Oncol. 2023 Aug;34(8):693-702. doi: 10.1016/j.annonc.2023.05.009. Epub 2023 Jun 1.
3
Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors.跨国分析与延长间隔固定剂量检查点抑制剂相关的估计医疗成本。
JAMA Netw Open. 2023 Feb 1;6(2):e230490. doi: 10.1001/jamanetworkopen.2023.0490.
4
Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.KN035（envafolimab）是一种新型皮下注射的、靶向 PD-L1 的单域抗体，在晚期实体瘤日本患者中的 I 期研究。
Invest New Drugs. 2022 Oct;40(5):1021-1031. doi: 10.1007/s10637-022-01287-7. Epub 2022 Aug 6.
5
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab.皮下注射利妥昔单抗引入后的患者护理和实践效率的真实世界评估。
Oncology (Williston Park). 2021 Dec 22;35(12):804-811. doi: 10.46883/2021.25920935.
6
Clinical evaluation of large volume subcutaneous injection tissue effects, pain, and acceptability in healthy adults.健康成年人中大体积皮下注射的组织效果、疼痛和可接受性的临床评价。
Clin Transl Sci. 2022 Jan;15(1):92-104. doi: 10.1111/cts.13109. Epub 2021 Nov 10.
7
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics.癌症免疫疗法更新：FDA 批准的检查点抑制剂和伴随诊断。
AAPS J. 2021 Mar 7;23(2):39. doi: 10.1208/s12248-021-00574-0.
8
Influence of physiochemical properties on the subcutaneous absorption and bioavailability of monoclonal antibodies.理化性质对单克隆抗体的皮下吸收和生物利用度的影响。
MAbs. 2020 Jan 1;12(1):1770028. doi: 10.1080/19420862.2020.1770028.
9
Differentiating characteristics and evaluating intravenous and subcutaneous immunoglobulin.区分特征并评估静脉注射和皮下免疫球蛋白。
Am J Manag Care. 2019 Jun;25(6 Suppl):S98-S104.
10
Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.评估抗 PD-1 抗体 PF-06801591 皮下注射与静脉注射用于晚期实体瘤患者：一项 I 期剂量递增试验。
JAMA Oncol. 2019 Jul 1;5(7):999-1007. doi: 10.1001/jamaoncol.2019.0836.
Zotero 插件